In studies comparing healthy controls and patients with relapsing–remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) who had not undergone treatment, both RRMS and SPMS patients exhibited a significantly higher proportion of CTLA-4+ CD4+ T cells compared to the healthy control group. This evidence concerns the gene CD4 and relapsing-remitting multiple sclerosis.